Progress in Cancer Immunotherapies

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 941

Special Issue Editors

E-Mail Website
Guest Editor
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: immunotherapy; immune receptor signaling; tumor microenvironment; cancer metastasis

E-Mail Website
Guest Editor
Garvan Institute of Medical Research, Sydney, Australia
Interests: computational biology; cancer genetics/genomics and epigenetics/epigenomics; machine learning

Special Issue Information

Dear Colleagues,

In recent years, the field of cancer immunotherapy has undergone a transformative evolution, emerging as a beacon of hope in the fight against cancer. This Special Issue "Progress in Cancer Immunotherapies" within the journal Cells embarks on a focused exploration of this dynamic domain, seeking to encapsulate the relentless advancements that have propelled immunotherapy to the forefront of oncological research.

Immunotherapy has redefined the treatment paradigm by harnessing the inherent capabilities of the immune system to recognize and eliminate cancer cells. From immune checkpoint inhibitors to adoptive cell therapies, the repertoire of immunotherapeutic strategies continues to expand, presenting unprecedented opportunities to revolutionize cancer care. This Special Issue aims to delineate the contours of this rapidly evolving landscape, concentrating on key aspects such as the development of novel agents, breakthroughs in understanding the intricate interplay of immune cells within the tumour microenvironment, and strides in personalized immunotherapy approaches.

By delving into the nuances of these pivotal areas, this Special Issue endeavours to serve as a compass, guiding researchers, clinicians, and stakeholders through the intricate maze of cancer immunotherapies. As we navigate this exciting frontier, the collective insights presented within this compilation strive to accelerate the translation of groundbreaking discoveries into tangible clinical outcomes, fostering a deeper understanding of the challenges and promises inherent in the pursuit of conquering cancer through the prism of immunological innovation.

Dr. Van Ngu Trinh
Dr. Phuc Loi Luu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cancer immunotherapy
  • immune checkpoint inhibitors
  • personalized immunotherapy
  • tumor microenvironment
  • biomarkers in immunotherapy

Published Papers

This special issue is now open for submission.
Back to TopTop